Role of Abl Kinase and the Wave2 Signaling Complex in HIV-1 Entry at a Post-Hemifusion Step by Harmon, Brooke et al.
Role of Abl Kinase and the Wave2 Signaling Complex in
HIV-1 Entry at a Post-Hemifusion Step
Brooke Harmon, Nancy Campbell, Lee Ratner*
Division of Molecular Oncology, Washington University School of Medicine, St Louis, Missouri, United States of America
Abstract
Entry of human immunodeficiency virus type 1 (HIV-1) commences with binding of the envelope glycoprotein (Env) to the
receptor CD4, and one of two coreceptors, CXCR4 or CCR5. Env-mediated signaling through coreceptor results in Gaq-
mediated Rac activation and actin cytoskeleton rearrangements necessary for fusion. Guanine nucleotide exchange factors
(GEFs) activate Rac and regulate its downstream protein effectors. In this study we show that Env-induced Rac activation is
mediated by the Rac GEF Tiam-1, which associates with the adaptor protein IRSp53 to link Rac to the Wave2 complex. Rac
and the tyrosine kinase Abl then activate the Wave2 complex and promote Arp2/3-dependent actin polymerization. Env-
mediated cell-cell fusion, virus-cell fusion and HIV-1 infection are dependent on Tiam-1, Abl, IRSp53, Wave2, and Arp3 as
shown by attenuation of fusion and infection in cells expressing siRNA targeted to these signaling components. HIV-1 Env-
dependent cell-cell fusion, virus-cell fusion and infection were also inhibited by Abl kinase inhibitors, imatinib, nilotinib, and
dasatinib. Treatment of cells with Abl kinase inhibitors did not affect cell viability or surface expression of CD4 and CCR5.
Similar results with inhibitors and siRNAs were obtained when Env-dependent cell-cell fusion, virus-cell fusion or infection
was measured, and when cell lines or primary cells were the target. Using membrane curving agents and fluorescence
microscopy, we showed that inhibition of Abl kinase activity arrests fusion at the hemifusion (lipid mixing) step, suggesting
a role for Abl-mediated actin remodeling in pore formation and expansion. These results suggest a potential utility of Abl
kinase inhibitors to treat HIV-1 infected patients.
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Introduction
HIV-1 enters cells in a pH-independent manner by fusion at the
plasma membrane or from within endosomes [1–3]. HIV-1 entry
requires multiple conformational changes in the HIV-1 glycopro-
tein, and rearrangement of the actin cytoskeleton. These events
are triggered by binding of the viral envelope (Env) surface subunit
gp120 to the primary receptor CD4 and one of two chemokine
coreceptors, CCR5 or CXCR4 [1,4]. This interaction activates
signaling events in the cell, similar to those initiated by natural
ligands, such as Ca
2+ mobilization, activation of RhoGTPases,
and phosphorylation of tyrosine kinases, pyk2, Zap70 and p56lck
[4–6]. Rho family GTPases, which include the Cdc42, Rac, and
Rho subfamilies, are responsible for regulating signaling from
membrane receptors to the actin cytoskeleton. The Rho sub-family
stimulates myosin based contractility, and drives the formation of
stress fibers and focal adhesions. The Rac sub-family stimulates
lamellipodia and membrane ruffles, and the Cdc42 subfamily
stimulates the formation of filopodia [7–9]. We showed that HIV-1
Env binding to target cells induces activation of Rac, stimulates
membrane ruffles and lamellipodia, and fusion is inhibited by
dominant negative Rac [4,10]. Furthermore, HIV-1 Env-induced
Rac activation depends on activation of Gaq, phospholipase C
(PLC), Ca
2+ mobilization, protein kinase C (PKC), pyk2 and the
GTPase Ras [5]. In the current study we identified the fusion-
specific effectors of Rac required for actin cytoskeleton rearrange-
ments that mediate membrane fusion and entry.
Guanine nucleotide exchange factors (GEFs) activate GTPases,
facilitating the GDP to GTP switch, and regulate their
downstream effects by participating in scaffolding protein
complexes, thereby linking GTPase activity to specific effectors
[7–9]. HIV-1 Env-induced Rac activation is mediated by a specific
Rac GEF, either Tiam-1 or Trio [10,11]. There are multiple
effectors of Rac, including serine/threonine kinases, lipid kinases,
actin-binding proteins, and adaptor/scaffold molecules [7,12].
PAK is a downstream effector of Rac and Cdc42 that promotes
stabilization of actin networks. Another downstream effector of
Rac that nucleates actin polymerization is the Arp2/3 complex.
The Arp2/3 complex is activated by the Wave2 complex through
IRSp53, an adaptor protein that binds Rac and Wave2 [7]. The
Wave2 complex includes Rac-associated protein 1, Nck-associated
protein, Abl-interacting protein 2, and heat shock protein C300.
Wave2 also associates with Abl, and Abl-mediated phosphoryla-
tion of Wave2 promotes its activation [13,14]. In addition to
determining which Rac effectors are critical for membrane fusion,
we studied the steps in the membrane fusion process affected by
these signaling molecules. These data demonstrate that the Wave2
signaling complex and Abl are required for Env-mediated
membrane fusion, entry, and infection and that Abl kinase
inhibitors arrest the fusion process at hemifusion.
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HIV-1 Env-Mediated Fusion Depends on the Wave2
Signaling Complex
To determine whether Abl, Trio, or Tiam-1 were required for
HIV-1 Env-mediated cell-cell fusion, expression of these proteins
was down regulated by RNA interference (RNAi) in
U87.CD4.CCR5 cells. Cells expressing siRNA were then mixed
with BSC40 cells expressing different Env subtypes and Env-
dependent cell-cell fusion was measured. Transfection of target
cells with siRNA to Tiam-1 and Abl decreased levels of Env-
mediated cell-cell fusion by an average of 7965% and 7465%
respectively for both HIV-1 R5 and dual-tropic Env-subtypes
(Figure 1A, left). There was no significant fusion observed with
CCR5 expressing target cells and X4 Env expressing cells with or
without siRNA, as expected. The decrease in the levels of fusion
correlated well with the decreased steady-state level of Tiam-1,
and Abl as detected by immunoblot (Figure 1C). A siRNA directed
against Trio had no effect on Env-induced cell-cell fusion despite a
70% reduction in expression of the Trio protein (Figure 1A and
C). To determine whether Tiam-1 and Abl are acting exclusively
upstream of Rac, a constitutively active Rac mutant, RacV12 was
expressed in siRNA transfected cells. Expression of RacV12 in
cells expressing siRNA to Tiam-1 reversed the effects of this
siRNA on fusion, suggesting that Tiam-1 is functioning upstream
of Rac. In contrast, levels of fusion in cells expressing RacV12 and
siRNA to Abl were only 5361% that of cells expressing RacV12
and control siRNA, suggesting a role for Abl upstream and
downstream of Rac (Figure 1A, right).
Tiam-1 binds to the Rac and Cdc42 effector IRSp53,
enhancing IRSp53 binding to Rac and activation of the Wave2
scaffolding complex [15]. To determine the role of these Rac
effectors in Env-mediated membrane fusion, their expression was
down regulated by RNAi in U87.CD4.CCR5 cells. The siRNA
expressing cells were mixed with Env-expressing cells and cell-cell
fusion was measured. Expression of siRNA to IRSp53, Wave2,
and Arp3 decreased fusion by 7465% 7764% and 7864%,
respectively. The decrease in fusion with these siRNAs was not
overcome by expression of RacV12, suggesting that these proteins
are required downstream of Rac (Figure 1B). The decrease in
levels of fusion correlated with the decrease in protein expression
in cells expressing these siRNAs, as seen by immunoblot
(Figure 1C), and each siRNA was specific for its target protein
(Figure S1A). Treatment of cells stably expressing siRNA resistant
Arp3, with Arp3 targeted siRNA had no effect on Env-mediated
cell-cell fusion (Figure 1D, E). In contrast, with untransfected cells,
and cells stably expressing siRNA resistant Arp3, treatment with
siRNA to Rac decreased fusion by 7565% and 7663%
respectively (Figure 1D). These results show that the effects of
RNAi on fusion were specific to inhibition of their target
molecules.
To demonstrate the role of Tiam-1, Abl, Rac, IRSp53, Wave2
and Arp3 in virus-cell fusion, their expression was down regulated
by RNAi in TZM-BL cells, a derivative of HeLa cells that express
CD4, CCR5, and CXCR4, and these cells were then used in a
Vpr-Blam assay [16,17]. In this assay siRNA expressing cells were
mixed for 90 min with HIV-1 strains with cores carrying a b-
lactamase (BlaM)-Vpr chimera, and pseudotyped with Env from
ADA (R5), YU2 (R5) or HXB2 (X4), and fusion was quantified by
measuring the cytosolic activity of viral core-associated BlaM [18].
Expression of siRNA to Tiam-1, Abl, Rac, IRSp53, Wave2, and
Arp3 decreased virus-cell fusion by an average of 8064%,
8361%, 7664%, 8266%, 7763% and 8266%, respectively,
for HIV-1 R5 and X4 Env subtypes (Figure 1F). These results
show that activation of the Wave2 signaling complex is required
for Env-dependent cell-cell fusion and virus-cell fusion.
Small Molecule Inhibitors of Abl Kinase Activity Inhibit
HIV-1 Entry
Since treatment of cells with Abl targeted siRNA led to a
decrease in Env-dependent cell-cell fusion and virus-cell fusion we
wanted to determine whether treatment of target cells with
commercially available Abl kinase inhibitors, imatinib (IMB),
nilotinib (NIL), and dasatinib (DAS), block fusion. IMB is a
relatively specific inhibitor of Bcr-Abl, Abl, Arg, and class III
receptor tyrosine kinases. NIL is an Abl kinase inhibitor 20–50 fold
more potent than IMB at inhibiting Abl. DAS, originally designed
as a Src family kinase inhibitor, antagonizes Abl, ephrin and
platelet-derived growth factor receptor kinases, and kit. DAS is
300 fold more potent than IMB at inhibiting Abl [19,20]. To
determine the concentrations of these Abl kinase inhibitors that
inhibit Abl kinase activity and Env-mediated cell-cell fusion,
without non-specific effects, Abl kinase activity, trypan blue
analysis, vaccinia virus infection, and T7 polymerase activity were
measured in addition to Env-dependent cell-cell fusion (Figure
S1B, S2, and data not shown). Treatment of U87.CD4.CCR5 cells
with 10 uM IMB, 500 nM NIL, and 300 nM DAS for 1 h prior to
and during 3 h incubation with Env-expressing cells decreased
Env-mediated cell-cell fusion by an average of 9562%, 9265%,
and 9266%, respectively, and Abl kinase activity by 85–87%
(Figure 2A and S1B). The CCR5 inhibitor TAK-779, which
completely blocks Env-mediated cell-cell fusion and infection of
CCR5 expressing cells, was included as a control, and it decreased
Env-dependent cell-cell fusion by 9961% and Env-mediated Abl
kinase activation by 98% (Figure 2A and S1B). Similar results were
observed with U87.CD4.CXCR4 cells treated with CXCR4
inhibitor AMD3100 and Abl kinase inhibitors and incubated with
cells expressing HIV-1 X4 or dual-tropic Env subtypes (Figure
S3A). There was no decrease in T7 polymerase activity, or
localization of CD4 and CCR5 on the cell surface (Figure S4 and
data not shown). Expression of RacV12 in U87.CD4.CCR5 cells
treated with IMB, NIL and DAS increased the level of fusion by
an average of 3.5-fold (*, P,0.05) compared to treated cells
without RacV12, suggesting a role of Abl kinase activity upstream
of Rac (Figure 2B).
To determine the effect of these Abl kinase inhibitors on Env-
induced Rac activation, U87.CD4.CCR5 cells were treated with
inhibitors for 1 h prior to mixing with BSC40 cells expressing no
HIV-1 Env, HIV-1 X4 Env, or HIV-1 R5 Env for 30 minutes in
Author Summary
Patients infected with HIV-1 are currently treated with
highly active antiretroviral therapy (HAART) that efficiently
suppresses the virus but does not cure the infection. HIV-1
envelope activates Rac-mediated actin cytoskeleton rear-
rangements in the target cell that promote membrane
fusion and entry. We discovered that these rearrange-
ments require activation of the actin polymerization
machinery including the tyrosine kinase Abl. We also
showed that Abl kinase inhibitors imatinib, nilotinib, and
dasatinib, current drug therapies for chronic myeloid
leukemia, block HIV-1 entry and infection. These results
suggest that these inhibitors might be appropriate drugs
for treatment of HIV-1. This strategy of using inhibitors that
disable host signaling proteins rather than viral proteins,
essential for pathogen survival, may have a general
efficacy in developing drugs to combat HIV-1 and other
pathogens that acquire drug resistance.
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induce Rac activation in CCR5 expressing cells, and the CCR5
inhibitor TAK-779, which completely blocks Env-mediated Rac
activation in CCR5 expressing cells, were included as controls [5].
Env-induced Rac activation was abolished in cells treated with
TAK-779, and all three of the Abl kinase inhibitors (Figure 2C).
To validate these effects in a relevant HIV-1 target cell, peripheral
blood lymphocytes (PBLs), which express CD4, CCR5 and
CXCR4, were used as the target cell population in an Env-
dependent cell-cell fusion assay. Treatment of PBLs with IMB,
NIL, and DAS decreased fusion by an average of 9261%,
9263%, and 99.561%, respectively, for HIV-1 R5, dual-tropic
and X4 Env subtypes (Figure 2D). The CCR5 inhibitor TAK-779,
as expected, completely blocked fusion mediated by R5 Env-
expressing cells, inhibited fusion mediated by dual-tropic Env by
5662%, and had no effect on fusion mediated by X4 Env
(Figure 2D).
A long term infection assay was also performed where PBLs
were infected with 150 ng of the X4 HIVHXB2 virus after 1 h
preincubation with no inhibitor, DMSO, 10 mM IMB, 250 nM
NIL, or 75 nM DAS. After 3 h, virus and inhibitors were washed
off, inhibitors were added back and the plate was incubated at 37u
for 21 days with addition of the inhibitors every 24 h. After 21
days the samples were assayed for cell viability and p24 antigen
content. Treatment with IMB, NIL, and DAS decreased cell
viability of HIVHXB2 infected cells by 1764%, 865%, and 863%
respectively and decreased infection by 52%, 51% and 94%
compared to DMSO treated cells (Figure S5).
To validate the specificity of these effects, we performed an Env-
dependent cell-cell fusion assay with cells stably expressing two
different drug resistant Bcr-Abl mutants (Y253F and T315I), or
expressing wild type (WT) Bcr-Abl [21]. Expression of the drug
resistant Bcr-Abl mutants but not WT Bcr-Abl resulted in recovery
of fusion (Figure 2E), demonstrating that the effects of these
Figure 1. Down regulation of Wave2 signaling complex with siRNA reduces HIV-1 Env-mediated cell-cell fusion and virus-cell
fusion. U87.CD4.CCR5 cells were transfected with control siRNA (control) or siRNA targeted against (A) Trio, Tiam-1, Abl, Rac, (B) IRSp53, Wave2, and
Arp3. Cells were serum starved 24 h post-transfection (pt), infected with vCB21R alone or with vRacV12 48 h pt, and 72 h pt cells were incubated for
3 h with HIVUNC (subtracted as background), HIVADA, HIVYU2, HIV89.6 or HIVHXB2 Env-expressing cells and b-gal activity was measured (C) Each
population of transfected cells was analyzed by Western blot with antibodies to the designated protein or actin. The relative reduction index (RI) is
the quotient of the densitometry signal for the target band and that for actin, normalized by the ratio obtained with control siRNA. (D) U87.CD4.CCR5
cells engineered to express a siRNA resistant clone of Arp3 were transfected with control siRNA, or siRNA targeted against Arp3 or Rac. Cell fusion was
measured by b-gal activity, and was normalized using control siRNA transfected cells incubated with HIVADA Env as 100%. (E) Western blots were
performed on siRNA-resistant U87.CD4.CC5 cells expressing siRNA-resistant Arp3. (F) TZM-BL cells were transfected with 200 nM of targeted siRNA
indicated and 48 h pt cells were incubated for 90 min with X4 HIVHXB2 virus R5 HIVADA virus or HIVYU2 virus. Fusion was stopped by adding lysis buffer
with BlaM substrate. Cells were then incubated at rt overnight in the dark. OD values for no virus samples was subtracted as background and percent
Blam activity was normalized using control siRNA transfected cells incubated with X4 HIVHXB2 virus as 100%. All data are representative of results from
three similar experiments performed in triplicate.
doi:10.1371/journal.ppat.1000956.g001
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inhibition of Abl.
To confirm these results using virus particles with relevant levels
of virus-associated glycoprotein, we used a virus-dependent cell-
cell fusion assay based on the ability of virus particles to bridge two
cells and allow transfer of cytoplasmic contents, and we also used
the Vpr-BlaM assay described above [4,10]. For the virus-
dependent cell-cell fusion assay we used two populations of
U87.CD4.CCR5 cells, one expressing the T7 polymerase and the
other expressing the b-galactosidase (b-gal) gene under the T7
promoter. Both populations were incubated with inhibitors for 1 h
prior to 3 h incubation with R5 virus HIVYU2. In this assay,
controls included untreated and inhibitor treated cells that were
not incubated with virus, the CCR5 inhibitor TAK-779, and T-20
which blocks entry by inhibiting the conformational change in
HIV-1 gp41 required for fusion [17]. R5 Virus-dependent cell-cell
fusion was reduced by an average of 9463% in cells treated with
IMB, DAS, and NIL compared to cells treated with DMSO alone,
and treatment with TAK-779 and T-20 completely inhibited
fusion (Figure 2F). Treatment of U87.CD4.CXCR4 cells incubat-
ed with the X4 virus HIVHXB2 with AMD3100 IMB, NIL, and
DAS decreased virus-dependent cell-cell fusion by 8867%,
98.661%, 8765%, and 96617%, respectively (Figure S3B).
For the Vpr-BlaM assay, TZM-BL cells were treated with 1 mM
AMD3100, 1 mM TAK-779, 10 mM IMB, 500 nM NIL and
150 nM DAS for 1 hr prior to and during the 90 min incubation
Figure 2. Abl kinase is required upstream and downstream of Rac for HIV-1 entry. (A) U87.CD4.CCR5 cells were infected with vCB21R
alone, or with (B) vRacV12 overnight, then treated with DMSO alone, TAK-779, IMB, NIL, or DAS for 1 h and the inhibitors were also present during 3 h
incubation with HIV-1 Env-expressing cells and b-gal activity as measured. (C) U87.CD4.CCR5 cells were treated for 1 h with TAK-779, IMB, NIL, or DAS
and during 30 min incubation with BSC40 cells expressing no Env (subtracted as background), HIVADA Env or HIVHXB2 Env. Whole cell lysates were
analyzed by Rac specific G-LISA activation assay. Average A490 of triplicate wells 6 standard deviation are shown. (D) PBMCs were infected with
vCB21R in complete media overnight, treated with DMSO, TAK-779, IMB, NIL, or DAS for 1 h prior to addition of HIV-1 Env-expressing cells and b-gal
activity was measured. (E) U87.CD4.CCR5 cells engineered to express indicated clones of Bcr-Abl were treated with Abl inhibitors and HIVUNC or
HIVADA Env as described above or analyzed by Western blot with anti-Abl or anti-actin antibody (inset). (F) U87.CD4.CCR5 cells were infected
overnight with vCB21R or vPT7-3, then mixed (1:1) in triplicate wells, treated for 1 h with DMSO, TAK-779, T20, IMB, NIL, DAS, and with 100 ng of
HIVYU2 for 3 h at 37uC. b-gal activity was measured and cell fusion was normalized using DMSO treated cells mixed with HIVYU2 as 100%. (G) TZM-BL
cells were treated with DMSO, 1 mM TAK-779 or AMD3100, 10 mM IMB, 500 nM NIL, or 150 nM DAS for 1 h prior to 90 min incubation with indicated
HIV viruses and BlaM activity was measured. Activity was normalized using DMSO treated cells mixed with HIVHXB2 virus as 100%. All data are
representative of results from three similar experiments performed in triplicate.
doi:10.1371/journal.ppat.1000956.g002
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AMD3100 treatment decreased X4-Vpr-BlaM activity by
8461%, but had no effect on R5-Vpr-BlaM activity. TAK-779
treatment decreased R5-Vpr-BlaM activity by an average of
8962%, but had no effect on X4-Vpr-BlaM activity, as expected.
However, treatment of TZM-BL cells with IMB, NIL, and DAS
decreased virus-cell fusion by an average of 8164%, 8965%, and
9061%, respectively, for both HIV-1 R5 and X4 Env subtypes
(Figure 2G). These results together with the results of the Env-
dependent and virus-cell fusion assay demonstrate that Abl kinase
is required for HIV-1 entry mediated by CXCR4 and CCR5.
Infection of TZM-BL Cells with HIV-1 Particles, but not
Particles Pseudotyped with Amphotropic Murine
Leukemia Virus (A-MLV) Env or Vesicular Stomatitis Virus
Glycoprotein (VSV-G), Depends on Abl and the Wave2
Signaling Complex
To determine whether the Wave2 signaling complex and Abl are
required exclusively for HIV-1 entry, or virus-induced fusion and
infection in general, we examined infection with HIV-1 versus A-
MLV Env (A-MLV-ENV-HIV-1) or VSV-G pseudotyped HIV-1
(VSV-G-HIV-1) using the TZM-BL assay. HIV-1 Env induces pH
independent virus-cell fusion to facilitate entry, whereas viruses
pseudotyped with VSV-G or A-MLV Env induce pH-dependent
clathrin mediated endocytosis or caveolin-mediated endocytosis,
respectively [22–25]. TZM-BL cells, a derivative of HeLa cells that
express CD4, CCR5, CXCR4, and luciferase (luc) under the control
of the HIV-1 LTR, were pretreated with the 10 mM IMB, 500 nM
NIL and 150 nM DAS for 1 h prior to incubation with virus for 3 h,
and a subsequent 24 h incubation with inhibitor only [16,17]. The
CCR5 inhibitor TAK-779, the CXCR4 inhibitor AMD3100, and
ammonium chloride (NH4Cl) whichinhibits endosomal acidification
required for VSV-G mediated entry, were included as controls
[22,23,26]. The top two panels of Figure 3A shows that treatment
with IMB, NIL,andDAS decreased infection with R5HIVYU2 virus
and X4 HIVHXB2 virus by an average of 9167%, 8864%, and
9165%, respectively, comparable to the reductions observed with
Env-dependent cell-cell fusion, virus-dependent cell-cell fusion and
virus-cellfusion (Figure 2).The Abl kinaseinhibitorshadnoeffecton
infection of TZM-BL cells with A-MLV-ENV-HIV-1 or VSV-G-
HIV-1, but treatment of cells with NH4Cl blocked infection with
VSV-G-HIV-1 as expected (Figure 3A, bottom two panels). These
data show that Abl-kinase inhibitors were able to block HIV-1 Env-
mediated fusion specifically and had no effect on infection via pH-
dependent clathrin-mediated or caveolin-mediated endocytosis, and
post-entry steps were not affected by these inhibitors.
To test the effect of Wave2 complex targeted siRNAs on
infection, TZM-BL cells were transfected with 200 nM control
siRNA or siRNA directed towards Tiam-1, Trio, Abl, IRSp53,
Wave2 and Arp3. These cells were incubated with virus for 3 h,
and media alone for 24 h. The decreased levels of HIV-1YU2 and
HIV-1HXB2 infection of TZM-BL cells expressing siRNA targeted
to Tiam-1, Abl, IRSp53, Wave2, and Arp3 were comparable to
levels of Env-mediated cell fusion with U87.CD4.CCR5 cells
expressing these siRNAs, whereas siRNA to Trio had no effect
(Figure 3B, top two panels). Steady state levels of target proteins in
cells expressing targeted siRNAs were decreased to similar levels as
in U87 cells (Figure 1C and data not shown). Infection of TZM-BL
cells with A-MLV-ENV-HIV-1 or VSV-G-HIV-1 was not affected
by expression of the targeted siRNAs, suggesting that Tiam-1, Abl,
IRSp53, Wave2, and Arp3 are required for HIV-1 Env-mediated
entry and are not necessary for post-fusion steps in the virus life
cycle (Figure 3B, bottom 2 panels).
The Abl Kinase Inhibitors Arrest Fusion at the Hemifusion
Step
HIV-1 Env-induced fusion, and release of the viral capsid into
the cytosol is a multistep process. First, gp120 binds to CD4
inducing conformational changes in gp120, and actin cytoskeletal
rearrangements in the target membrane that bring the coreceptor
CCR5 or CXCR4 into close proximity with CD4. Next,
coreceptor binding to gp120 triggers conformational changes in
gp41 to produce a prebundle conformation that inserts into the
target cell membrane, allowing lipid mixing or hemifusion, and
then pore formation. Additional conformational changes induce
formation of the gp41 6-helix-bundle which prevents pore closure
and facilitates pore enlargement and full fusion [2,27,28]. To
determine which step(s) in the membrane fusion process are
blocked by the Abl kinase inhibitors, we examined the effect on
infection of membrane curving agents. Oleic acid (OLA),
chlorpromazine (CPZ), and trifluoperazine (TFP) are lipid analogs
that insert into the inner leaflet of the cell membrane. OLA
induces negative curvature in the membrane that promotes
formation of a hemifusion intermediate (i.e. lipid mixing), but
cannot induce pore formation if there is a block at hemifusion.
CPZ and TFP are membrane-permeable weak bases that partition
into inner leaflets of cell membranes, induce positive curvature,
and relieve a block at hemifusion [29–32].
To determine the effect of inhibitors and lipid analogs on HIV-1
infection, TZM-BL cells were treated with 1 mM AMD3100,
1 mM TAK-779, 10 mM IMB, 500 nM NIL, and 150 nM DAS
for 1 h, prior to and during 1 h incubation with no virus,
HIVDENV, R5 HIVYU2, X4 HIVHXB2, A-MLV-ENV-HIV-1, or
VSV-G-HIV-1. After 1 h, cells were treated with CPZ or TFP for
1 min or OLA for 5 min, followed by 2 h incubation with
inhibitor and virus, and subsequent 24 h incubation with inhibitor
only. Addition of CPZ and TFP to cells treated with Abl kinase
inhibitors and infected with HIVYU2 or HIVHXB2 resulted in an 8
fold increase in infection compared to inhibitor treated cells
infected in the absence of lipid analogs (Figure 4A), The exogenous
cone shaped lipid OLA, which induces negative curvature of the
membrane resulting in lipid mixing, had no affect on infection
(Figure 4A). TAK-779 mediated inhibition of HIVYU2 infection
and AMD3100 mediated inhibition of HIVHXB2 infection was not
affected by these lipid analogs. No increase in luc activity was
observed with lipid analog treatment of cells infected with
HIVDENV versus no virus, indicating that Env is required to
observe an increase in infection (Figure S6A). Treatment of A-
MLV-ENV-HIV-1 and VSV-G-HIV-1 infected cells with CPZ
and TFP decreased overall infection by 2 fold and had no effect on
cells treated with Abl kinase inhibitors, indicating that the increase
in HIV-1 infection observed with Abl kinase inhibitor treated cells
was specific (Figure 4A, lower panels). CPZ also partially reversed
the inhibitory effects of nilotinib as measured by the Vpr-BlaM
assay (Figure S6B).
Similar increases in virus-dependent cell-cell fusion were
observed when U87.CD4.CCR5 cells were treated with inhibitors
and lipid analogs and HIVYU2 mediated fusion was measured after
3 h (Figure S6C). Cells were also incubated with the lipid analogs
in the absence of HIVYU2 to account for the effects of these agents
on the cells and on T7 polymerase activity. Addition of OLA did
not increase fusion in cells treated with any of the inhibitors
(Figure S6B). To confirm the results obtained with the Abl kinase
inhibitors we incubated TZM-BL cells transfected with Tiam-1,
Abl, Rac, IRSp53, Wave2, and Arp3 targeted siRNA, for 1 h with
no virus, HIVDENV, R5 HIVYU2, or X4 HIVHXB2. After 1 h cells
were treated with CPZ for 1 min or OLA for 5 min, followed by
2 h incubation with virus, and subsequent 24 h incubation with
Activation of Abl and Wave2 for HIV Entry
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siRNA transfected cells with CPZ increased infection by an
average 8.4 fold compared to untreated cells, and OLA had no
effect (Figure 4B). These results suggest that inhibition of Tiam-1,
Abl, Rac, IRSp53, Wave2 or Arp3 arrests fusion at hemifusion,
preventing pore formation, pore enlargement and content mixing.
To confirm that Abl kinase inhibitors cause arrest at hemifusion,
we used a modification of a fusion assay described previously [33].
CHO-K1 cells that lack expression of the lipid ganglioside GM1,
were engineered to express GFP and the HIV-1ADA (R5) Env
protein. U87.CD4.CCR5 cells were used as the target cell, and
lipid mixing was detected when GM1, detected by a TRITC-
conjugated form of cholera toxin b-subunit (CTX), was transferred
from the target cell to CHO-K1-GFP cells. Complete fusion is
detected when cells express GM1, GFP, and are multinucleated.
Quantification was performed for three independent experiments
and the percentage of hemifused GFP+, GM1+ cells with single
nuclei and the percentage of multinucleated fully fused cells was
enumerated for 68 cells from each condition (Figure 5, S7, and
Table S1) There were 83.1610.9% hemifused cells with IMB-
treated cells mixed with HIVADA-expressing CHO-K1 cells
(Figure 5), compared to DMSO treated cells with 22.364.9%
hemifused cells and 75.566.2% fully fused cells. With no HIV-1
Env or with the addition of TAK-779 there was little or no
hemifusion or full fusion (Figure 5).
To demonstrate the effects of the lipid analog CPZ on HIV-1
Env mediated cell-cell fusion and to observe the effect of CPZ and
the Abl kinase inhibitors on A-MLV Env or VSV-G induced cell-
cell fusion we treated U87.CD4.CCR5 cells with DMSO, TAK-
779, or IMB for 1 hr prior to incubation with CHO-K1 cells
expressing no Env, HIVADA, A-MLV Env or VSV-G for 1 hr.
After 1 h cells were treated with CPZ for 1 min and OLA for
5 min, then washed and incubated with inhibitor for an additional
2 h prior to fixation and GM1 staining. Incubation of IMB treated
cells with HIVADA and CPZ promoted the transition from
hemifusion to full fusion as expected (Figure S8). Fusion of A-
MLV Env and VSV-G Env expressing cells with U87.CD4.CCR5
cells was unaffected by treatment with IMB or CPZ (Figure S9)
Figure 3. Infection with HIV-1 particles but not particles pseudotyped with MLV Env or VSV-G depends on the Abl and Wave2
signaling complex. (A) TZM-BL cells were incubated for 1 h with DMSO, TAK-779, AMD3100, NH4Cl, IMB, NIL, or DAS and 150 ng of HIVHXB2, HIVYU2,
A-MLV-or VSV-G-HIV-1 per well was added for 3 h, washed, and cells were incubated with inhibitors overnight and luc activity was measured. (B)
TZM-BL cells were transfected with control siRNA or siRNA directed against indicated target proteins and 48 h later infected with 150 ng of HIVHXB2,
HIVYU2, A-MLV- or VSV-G-HIV-1 for 3 h, cells were washed and incubated overnight, and luc activity measured. Cell infection was normalized using (A)
DMSO treated cells or (B) cells transfected with control siRNA as 100%. All data are representative of results from three similar experiments performed
in triplicate.
doi:10.1371/journal.ppat.1000956.g003
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(data not shown). These results confirm that Abl kinase activity is
required at a post-hemifusion step for HIV-1 Env mediated fusion
and entry.
Discussion
Dynamic regulation of the actin cytoskeleton is required for
fusion of biological membranes. Multiple reports have demon-
strated that actin remodeling is required for HIV-1 mediated
fusion and entry [4,5,10,11,34–36]. Some studies showed that
treatment of target cells expressing physiologically relevant levels
of receptor and coreceptor with the actin filament capping drug
cytochalasin D prevented the formation of the gp120-CD4-
coreceptor complex [35,37,38]. Another more recent study,
demonstrated a role for CD4 and coreceptor-mediated filamin-A
interactions in receptor clustering that is dependent on RhoA and
ROCK mediated phosphorylation of ADF/cofilin [34]. Previous
work from our lab with the actin filament stabilizing drug
jasplakinolide and the actin monomer sequestering drug latruncu-
lin A (LA) suggested a role for actin remodeling at a post binding
step in fusion [4]. To further substantiate the role of actin
polymerization in HIV-1 entry, we treated cells with 1 mM LA and
5 mM latrunculin B (LB). Both drugs blocked HIV-1 fusion for
multiple cell types, as measured by the Env-dependent cell-cell
fusion assay, the virus-dependent cell-cell fusion assay, the virus-
cell fusion assay, and infection (Figure S10).
Our previous data demonstrated that the GTPase Rac was
activated by HIV-1 Env ligation of CCR5, resulting in membrane
ruffles and lamellipodia in the target cell membrane. Inhibition of
this activation by dominant negative Rac or by a Rac GEF
inhibitor completely abolished Env-dependent cell-cell fusion,
virus dependent cell-cell fusion and infection [4,5,10,11]. Our lab
went on to show that Env-induced Rac activation is mediated by
Gaq and its downstream effectors, including Ras. Other studies
showed that Ras promotes Rac activation via direct interaction
with Tiam-1, or by phosphatidylinositol 3-kinase (PI3K)-mediated
activation of Tiam-1 [39]. Env-dependent Rac activation likely
occurs through the first mechanism, since treatment of target cells
with PI3K inhibitors had no effect on Env-dependent cell-cell
fusion [40].
The nonreceptor tyrosine kinase, Abl, modulates actin upstream
and downstream of Rac [41,42]. In the current study, we used
siRNAs and specific inhibitors to show that the activity of Abl
kinase is required both upstream and downstream of Rac for Env-
induced membrane fusion. Upstream of Rac, Abl phosphorylation
of the Ras GEF complex promotes the activity of the Rac GEF
Tiam-1, which was shown in the current study to be required for
HIV-1 fusion. Downstream of Rac, Abl promotes phosphorylation
and activation of Wave2 and its interaction with the Arp2/3
complex, events also demonstrated here to be critical for HIV-1
infection, but not VSV-G or A-MLV Env-mediated infection.
These results suggest that these signaling mediators are important
Figure 4. Abl kinase inhibitors and expression of siRNA targeted to the Wave2 complex block HIV-1 Env-mediated infection at a
post-hemifusion step. (A) TZM-BL cells were treated with DMSO, TAK-779, AMD3100, IMB, NIL, or DAS for 1 h. HIVYU2 HIVHXB2, A-MLV-Env-HIV-1 or
VSV-G-HIV-1 (150 ng) was added for 1 h then cells were then treated with indicated lipid analogs for 1–5 min. Cells were washed and incubated in
inhibitor overnight and luc activities were measured. (B) TZM-BL cells were transfected with 200 nM control siRNA or siRNA targeted to Tiam-1, Abl,
Rac, IRSp53, Wave2 or Arp3 and 48 h pt cells were incubated with 150 ng of HIVYU2 or HIVHXB2. After 3 h cells were washed and incubated at 37u in
complete media overnight and luc activities were measured. Data are representative of results from three similar experiments performed in triplicate.
Cell infection was normalized using DMSO treated cells or control siRNA transfected cells infected with HIVYU2 or HIVHXB2 as 100%.
doi:10.1371/journal.ppat.1000956.g004
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dependent clathrin or caveolin-mediated endocytosis, and are
not required at post-entry steps in the virus life cycle.
There is some conflict in the literature as to the location and
mechanism of virus cell fusion. A recent report used microscopic
imaging to track HIV-1 Env-pseudotyped MLV virus particles and
observed virus-membrane fusion in endosomes [3]. This study also
showed that virus-cell fusion and infection were inhibited in the
presence of the dynamin inhibitor dynasore (DYN) which is known
to block both clathrin and caveolin-mediated endocytosis [3]. The
results in our current study suggest that fusion is occurring via a
mechanism that is distinct from that of VSV (clathrin-mediated
endocytosis) or A-MLV (caveolin-mediated endocytosis). In order
to address this conundrum, we treated cells with the dynamin
inhibitor DYN, and then used these cells for the Env-dependent
cell-cell fusion assay, the virus-dependent cell-cell fusion assay, the
virus-cell fusion assay and the TZM-BL infection assay. DYN
treatment decreased HIV-1 Env-mediated infection and virus-cell
fusion by an average of 5867% and 5063% respectively (Figure
S10 and Figure S11). However treatment with DYN decreased A-
MLV-Env-HIV-1 infection and VSV-G-HIV-1 infection by
7565% and 8961% respectively, showing that the affect on
HIV-1 Env-mediated infection was not as significant (Figure S11).
DYN treatment also decreased Env-dependent cell-cell fusion and
virus-dependent cell-cell fusion by 5368% and 50610%,
respectively which was unexpected since these assays both measure
cell-cell plasma membrane fusion. Dynamins are a group of large
GTPases that are involved in multiple processes in addition to
endocytosis, such as vesicle transport, cytokinesis, organelle
division, cell movement and cell signaling [43–45]. Therefore,
the inhibition observed with the dynamin inhibitor DYN could be
due to nonspecific effects on cellular processes. In support of this
conclusion, a recent study used the Rev-dependent indicator cell
line Rev-CEM to study the effects of DYN on HIV-1 replication
and VSV-G-HIV-1 infection [44]. Using this assay they observed
a dosage dependent decrease in VSV-G-HIV-1 infection with
DYN treatment but did not see any decrease in HIV-1 infection
[44]. These results as well as the results in Figure 3 show a clear
distinction between HIV-1 Env-mediated entry and VSV-G- and
A-MLV-mediated entry.
The current study also showed that the block in fusion caused
by inhibition of Tiam-1, Abl, Rac, IRSp53, Wave2 and Arp3
occurs after hemifusion and before cytoplasmic mixing. This
conclusion was based on the 1) confocal microscopy demonstra-
tion that addition of IMB to the fusion reaction allowed membrane
but not cytoplasmic mixing, and 2) observation that lipid analogs
that overcome a block at hemifusion overcame inhibition of HIV-
1 virus dependent cell fusion, virus-cell fusion and infection caused
by Abl kinase inhibitors and siRNA expression. These results
support a model whereby HIV-1 Env binding to CCR5 stimulates
Figure 5. Abl kinase inhibitors arrest HIV-1 Env-mediated fusion at the hemifusion step. CHO-K1 cells that do not express GM1 were
transfected with a GFP expressing plasmid (green), and 24 h later infected with WT vaccinia virus or vaccinia virus expressing HIVADA Env. After
another 24 h, CHO-K1 cells were overlaid for 3 h with U87.CD4.CCR5 cells pre-treated for 1 h with DMSO, TAK-779, or IMB. Cells were fixed and
stained with CTX-555 (red), and counterstained with TO-PRO 3 (blue). Images were collected using an oil objective (magnification X63). Images were
cropped but relative cell size was maintained. The percentage of hemifused cells is listed.
doi:10.1371/journal.ppat.1000956.g005
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interacts with IRSp53. IRSp53 promotes Rac activation of the
Wave2 complex, which is also activated by Abl, and activated
Wave2 induces subsequent activation of Arp2/3-mediated actin
rearrangements which facilitate pore formation, pore enlargement,
and entry of HIV-1.
Many microbial pathogens depend on Abl family kinases to
mediate efficient infection of their targeted host, including Shigella
flexneri, enteropathogenic Escherichia coli, Helicobacter pylori, Anaplasma
phagocytophilum, coxsackievirus, poxvirus, and murine AIDS virus.
Abl kinases are involved in pathogen entry, intracellular movement,
and exit from target cells; proliferation of target cells; and
phosphorylation of microbial effectors. Many of these processes
involve reorganization of the target cell actin cytoskeleton and
depend on the same signaling pathways as HIV-1 [4,5,46].
Discovery of these signaling mediators as fundamental components
of microbial pathogenesis provides new targets for therapeutic
intervention.TheclinicalapplicationofIMB,NIL,and DAS,which
block deregulated Abl kinases in leukemia patients, demonstrate
thatinhibitioninvivoispossiblewithmanageablesideeffects[19,20].
In addition IMB has been shown to be an effective inhibitor of anti-
apoptotic pathways induced by HIV-1 in macrophages [47]. Most
current antiviral therapies target viral proteins and mutation of the
virus leads to therapy resistance. Therefore, using inhibitors that
target host signaling proteins essential for HIV-1 entry may be an
efficient new strategy for treatment of infected patients.
Materials and Methods
Reagents and Cell Lines
U87.CD4.CCR5 cells are astroglioma cells expressing CD4,
CCR5-GFP or HA-CCR5. U87.CD4.CXCR4 cells are astro-
glioma cells expressing CD4 and CXCR4-GFP. CHO-K1 cells
(ATCC) were grown in F-12K media with 10% serum and other
cells maintained as described [48]. pMSCVneo-WT, Y253F, and
T315I Bcr-Abl were gifts from Dr. R. Van Etten [21]. The siRNA
resistant mutations were generated in Arp3 based on sequences
obtained from Santa Cruz Biotechnology, Inc (SCBT, Santa Cruz,
CA,), by PCR-mediated mutagenesis of a sub fragment that was
sequenced to confirm the presence of mutations before sub cloning
into the corresponding cDNA. WT and mutant cDNAs were
cloned in pcDNA3.1
+zeo for expression by transduction. IMB,
NIL, and DAS were from LC Laboratories and were used at
10 uM, 500 nM, and 300 nM respectively unless indicated; CPZ
(0.5 mM), TFP (0.3 mM), OA (100 nM), OLA (50 uM) and
NH4Cl (50 mM) were from Sigma; TAK-779 (1 uM), and T-20
(10 ug/ml) were from the AIDS Research and Reference Reagent
Program. The control siRNA constructs (non-targeting 20–25 nt
siRNA designed as a negative control), the siRNA constructs and
antibodies used for Western blots were from SCBT [5]. The
siRNA constructs were transfected using GeneEraser siRNA
Transfection Reagent or Lipofectamine RNAiMAX Transfection
Reagent according to the manufacturer’s instructions (Stratagene,
La Jolla, CA, Invitrogen, Carlsbad, CA).
Viruses
Wild-type (WT) vaccinia (WR strain) and recombinant vaccinia
viruses expressing b-galactosidase (vCB21R), T7 polymerase
(vPT7-3), constitutively active Rac GTPase (vRacV12), or HIV-
1 Env proteins were described [48]. HIV with R5 YU2 or X4
HXB2 Env in HIVNL4-3 backbone were generated from 293T
cells; some were pseudotyped with amphotropic murine leukemia
virus (MLV) or vesicular stomatitis virus (VSV) glycoproteins [5].
TZM-BL assays were performed as described [5]. For the BlaM
assay pseudoviruses were produced by co-transfecting 293T cells
with HIVNL4-3DVpr expressing YU2, ADA, or HXB2 Env and
BlaM-Vpr expressing pMM310 vector. Transfected 293T cell
supernatants were harvested 48 h postlipofection, filtered, and
assayed for p24 antigen content by enzyme-linked immunosorbent
assay. Viruses were resuspended in culture media, aliquoted and
stored at 280uC.
BlaM Assay for Virus-Cell Fusion
TZM-bl cells were serum starved for 24–36 h then plated
(4610
4 cells/well) in 96-well plates in complete media overnight.
Cells were treated with indicated concentrations of inhibitors for
1 hr prior to and during 90 min incubation with DEAE-dextran
(20 mg/ml) alone or DEAE-dextran (20 mg/ml) and 150 ng p24
HIVYU2Vpr-BlaM, HIVADAVpr-BlaM, or HIVHXB2Vpr-BlaM.
After 90 min virus and media were aspirated off cells and 100 ul
1X Lysis and Detection Solution was added to wells (LyticBlazer-
BODIPY FL, Invitrogen). The plate was incubated at room
temperature in the dark overnight. The BlaM activity was
quantified using TECAN fluorescence plate reader (Tecan,
Switzerland). The extent of virus-cell fusion was measured with
excitation centered at 485 nm and emission centered at 535 nm.
The green signal for samples incubated with no inhibitors or
inhibitors and no virus was subtracted as background from their
respective virus treated samples.
TZM-BL Assay
TZM-BL cells were serum starved for 12–24 h then plated
overnight in complete media in 96 well plate at 2610
4 cells per
well. Cells were treated for 1 h with indicated concentrations of
inhibitors prior to addition of media alone or 150 ng p24 of
HIVYU2 HIVHXB2 or VSVG or A-MLV-pseudotyped HIV in the
presence of 20 ug/ml DEAE-dextran for 3 h at 37uC. After 3 h
cells were washed 3 times with PBS and inhibitors were added in
fresh media. Following a 24 h incubation cells were lysed and
luciferase (luc) units determined. Infected wells and uninfected
wells with inhibitor were compared to wells with no inhibitor. For
the TZM-Bl assay with lipid analogs serum starved TZM-BL cells
were treated with inhibitors for 1 h, then 150 ng of indicated virus
was added for 1 h prior to treatment with CPZ or TFP for 1 min
or OLA for 5 min. Cells were washed three times with PBS and
virus and inhibitors were added back. After 2 h cells were washed
two times with PBS and incubated in inhibitor overnight and luc
activities were measured.
Long-Term PBMC Infection and Viability Assay
PBMCs that were isolated and stimulated as previously described
[5]. They were plated at 5610
5 cells per well in 96 well plate and
were treated with 10 mM IMB, 250 nM NIL, or 75 nM DAS for
1 h prior to addition of 150 ng p24 of HIVHXB2 in the presence of
20 ug/ml DEAE-dextran for 3 h at 37uC. After 3 h cells were
washed three times with PBS and incubated in inhibitor for 24 h.
Inhibitors were added back at the same concentration every 24 h
for three weeks. 100 ul of supernatant was collected every fourth
day and all samples were assayed for p24 antigen content by
enzyme-linked immunosorbent assay. Two separate plates were set
up under the exact same conditions and one plate was used for p24
measurement and the other was incubated with 20 ul cell viability
substrate per 100 ul of sample (Promega, Madison, WI).
Fusion and Hemifusion Assays
Envelope-mediated and virus-dependent fusion assays were
described. Average fusion compared to untreated control reactions
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To account for any effect of inhibitors on vaccinia virus infection
and/or on T7 polymerase function, vCB21R and vPT7-3 co-
infected cells were similarly treated with inhibitors. Concentration
curves were performed with all of the inhibitors to determine the
concentration that resulted in the maximum decrease in fusion
without altering vaccinia virus infection or T7 polymerase activity.
Hemifusion assays were performed with 2610
6 CHO-K1 cells
nucleofected with a GFP expression plasmid, and after 24 h
infected with vaccinia virus expressing HIVADA Env or no Env.
After 16 h, 4610
5 U87.CD4.CCR5.HA cells were added for 3 h,
fixed with paraformaldehyde, stained with TRITC-conjugated
CTX-555 (EMD), and analyzed on a 510 Meta LSM confocal
microscope.
Statistical Analysis
Fusion and infectivity results were compared using a two-tailed
t-test. All p values, unless indicated, were ,0.03.
Supporting Information
Figure S1 Abl is activated by HIV-1 Env and pretreatment with
inhibitors and siRNA results in specific effects on target molecule.
(A) U87.CD4.CCR5 cells were transfected with 200 nM control
siRNA or siRNA directed against Trio, Tiam-1, Abl, IRSp53,
Wave2, Arp3 and Rac and 48 h later each population of
transfected cells was lysed and analyzed by western blot with
antibodies to the designated protein or actin. The relative
reduction index (RI) is the quotient of the densitometry signal
for the target band and that for actin, normalized by the ratio
obtained with control siRNA. Data are from 1 of 3 experiments
with similar results. The bottom blot depicting Rac levels in cells
transfected with the siRNA targeted to control (lane 1), Trio (lane
2), Tiam-1 (lane 3), Abl (lane 4), Rac (lane 5), IRSp53 (lane 6),
Wave2 (lane 7), or Arp2/3 (lane 8) demonstrates that the siRNAs
have no effect on Rac expression. (B) Abl kinase activity was
measured using PAthScan Bcr/Abl activity assay from Cell
Signaling. Depicted is western blot analysis of a downstream
target of activated Abl kinase, phosphorylated CrkL, and loading
control eIF4E from lysates of U87.CD4.CCR5 cells mixed 1:1
with BSC40 cells expressing no Env (lane 1) or Env from HIV-1
strain ADA (lanes 2–5) at 37uC for 20 min. Cells were pretreated
with DMSO alone (NI), 1 uM TAK-779, 10 uM IMB, 500 nM
NIL, or 300 nM DAS for 1 hr and during the 20 min incubation
with Env-expressing cells. Cell lysates were resolved by 10% SDS-
PAGE, transferred to a nitrocellulose membrane, and probed with
phosphospecific primary antibody cocktail and anti-rabbit or anti-
biotin secondary. Blots shown are from 1 of 3 independent
experiments with similar results.
Found at: doi:10.1371/journal.ppat.1000956.s001 (2.44 MB TIF)
Figure S2 Abl kinase inhibitors decrease Env-induced fusion,
virus-dependent fusion and infection of TZM-BL cells with R5 and
X4 virus in a concentration dependent manner. Average fusion
compared to untreated control reactions was detected by b-gal
activity 6 standard deviation. (A) Serum starved U87.CD4.CCR5
cells were infected with vCB21R alone, or with vRacV12 overnight,
and then treated with DMSO alone, 1 uM TAK-779 or 1, 5, or
10 uM IMB, for 1 h and the inhibitors were also present during
the 3 h incubation with HIVUNC (subtracted as background)
HIVADA, HIVYU2, HIV89.6 or HIVHXB2 Env-expressing cells. (B)
U87.CD4.CCR5 cells were infected overnight with vCB21R or
vPT7-3, then mixed (1:1) in triplicate wells, treated for 1 h with
DMSO, 1 uM TAK-779, or 1, 5, or 10 uM IMB, and 100 ng of
HIVYU2 added for 3 h at 37uC. Cell fusion was normalized using
DMSO treated cells mixed with HIVYU2. (C) TZM-BL cells were
incubated for 1 h with DMSO, 1 uM TAK-779, 1, 5 or 10 uM
IMB, and 150 ng of HIVYU2 or 150 ng HIVHXB2 per well was
added for 3 h, washed, and cells were incubated with inhibitors at
37uC overnight. (D) Serum starved U87.CD4.CCR5 cells were
infected with vCB21R alone, or with vRacV12 overnight, then
treated with DMSO alone, 125, 250 or 500 nM Nilotinib, or (E)
DMSO alone, 75, 150 or 300 nM Dasatinib, for 1 h and the
inhibitorswerealsopresentduringthe3 h incubation withHIVUNC
(subtracted asbackground)HIVADA,HIVYU2,HIV89.6orHIVHXB2
Env-expressing cells. Data are representative of results from three
similar experiments.
Found at: doi:10.1371/journal.ppat.1000956.s002 (2.88 MB TIF)
Figure S3 Abl kinase is required for X4 Env-dependent and X4
virus-dependent cell-cell fusion. For Env-dependent fusion assays,
U87.CD4.CXCR4 cells were infected with vCB21R overnight
then treated with DMSO alone, AMD3100, IMB, NIL, or DAS
for 1 h and the inhibitors were also present during 3 h incubation
with HIV-1 Env-expressing cells and b-gal activity as measured.
For X4 virus-dependent fusion assays, U87.CD4.CXCR4 cells
were infected overnight with vCB21R or vPT7-3, then mixed (1:1)
in triplicate wells, treated for 1 h with DMSO, AMD3100, IMB,
NIL, DAS, and with 250 ng of HIVHXB2 for 5 h at 37uC. b-gal
activity was measured and cell fusion was normalized using
DMSO treated cells mixed with HIVHXB2 as 100%.
Found at: doi:10.1371/journal.ppat.1000956.s003 (0.89 MB TIF)
Figure S4 Abl kinase inhibitors do not affect surface expression
and localization of CD4 and CCR5.GFP. (A) Confocal micro-
graphs of U87.CD4.CCR5 cells treated with DMSO alone, TAK-
779 (1 uM), Imatinib (10 uM), Nilotinib (500 nM), Dasatinb
(300 nM) and RacGEF Inhibitor (100 uM) for 3 h, and CD
(1 uM) for 15 min, fixed and stained with anti-CD4-PE antibodies
(Sigma, red) and counterstained with TO-PRO3 (blue). The green
GFP signal and red PE signal have been merged to show areas of
colocalization (yellow). Images are from 1 of 3 experiments with
similar results. Images were collected using an oil objective
(magnification X63). The Nilotinib panel is a consolidation of 2
separate images from the same experiment. (B) U87.CD4.CCR5
cells were incubated with no inhibitor, DMSO alone, TAK-779
(1 uM), Imatinib (10 uM), Nilotinib (500 nM), Dasatinb (300 nM)
and RacGEF Inhibitor (100 uM) for 3 h and detached by
treatment with 5 mM EDTA. U87 cells, and untreated and
treated U87.CD4.CCR5.GFP cells, were stained with anti-CCR5
(R&D) or anti-CD4 antibodies (Sigma), and goat anti-mouse PE
conjugated antibody. Cells were analyzed on a FACS Calibur flow
cytometer. Unlabeled U87.CD4.CCR5.GFP cells were used to
compensate for GFP. Data are expressed as percentage of surface
expression based on DMSO treated cells as 100%.
Found at: doi:10.1371/journal.ppat.1000956.s004 (8.02 MB TIF)
Figure S5 Treatment of PBLs with Abl kinase inhibitors for 3
weeks blocks infection of X4 HIVHXB2 virus without significant
cell toxicity. PBLs were treated for 1 h with no inhibitor, DMSO,
10 mM IMB, 250 nM NIL, or 75 nM DAS for 1 h prior to and
during infection with 200 ng HIVHXB2 virus for 3 h. After 3 h
virus and inhibitor were washed off, inhibitor was added back and
cells were incubated at 37u for 24 h. Every 24 h for 21 days
inhibitor was added back at the same concentration. At day 21,
supernatants were harvested and p24 antigen content was
measured or cells were harvested and cell viability was assayed.
P24 content and cell viability were normalized using no inhibitor
treated cells infected with HIVHXB2 virus as 100%.
Found at: doi:10.1371/journal.ppat.1000956.s005 (1.14 MB TIF)
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OLA have no effect on infection with HIV-1DEnv, but positive
membrane curving lipid analogs overcome Abl kinase induced
inhibition of R5 HIVYU2 virus-dependent cell-cell fusion and X4
HIVHXB2 virus-cell fusion. (A) TZM-BL cells were treated with
DMSO, TAK-779, IMB, NIL, or DAS for 1 h prior to 1 h
incubation with 150 ng of HIV-1DEnv (B) TZM-BL cells were
treated with DMSO, or NIL for 1 hr prior to 1 h incubation with
150 ng HIVHXB2 virus (C) U87.CD4.CCR5 cells infected with
vCB21R or vPT7-3 overnight, then mixed (1:1) in triplicate wells of
96 well plate were treated with DMSO, TAK-779, IMB, NIL, or
DAS for 1 h prior to 1 h incubation with 100 ng of HIVYU2.A f t e r
1 h indicated lipid analogs were added for 1–5 min (A) cells were
washed, and virus and inhibitors were added back for (A, C) 3 h or
(B) 90 min and (A) cells were washed and incubated in inhibitor
overnight and luc activities were measured or (B) BlaM activity was
measured or(C)b-galactivitywasmeasured.Dataarerepresentative
of results from three similar experiments. Cell fusion was normalized
using DMSO treated cells incubated with HIVYU2 as 100%.
Found at: doi:10.1371/journal.ppat.1000956.s006 (0.67 MB TIF)
Figure S7 Abl-kinase inhibitors block fusion at a post-hemifu-
sion step. CHO-K1 cells that do not express GM1 were
transfected with a GFP expressing plasmid, and 24 h later infected
with wildtype vaccinia virus or vaccinia virus expressing HIVADA.
After another 16 h, CHO-K1 cells were overlayed for 3 h with
U87.CD4.CCR5 cells pre-treated for 1 h with DMSO, 1 mM
TAK-779, or 10 mM IMB. Cells were fixed and stained with
TRITC-conjugated CTX (CTX-555, red), and counterstained
with TO-PRO3 (blue). Images were collected using an oil
objective (magnification X63). Images were cropped but relative
cell size was maintained.
Found at: doi:10.1371/journal.ppat.1000956.s007 (7.02 MB TIF)
Figure S8 IMB induced arrest at hemifusion step is overcome
with membrane curving lipid analog CPZ. U87.CD4.CCR5 cells
were pre-treated for 1 h with DMSO, 1 mM TAK-779, or 10 mM
IMB, incubated with CHO-K1 cells expressing no Env or
HIVADA Env for 1 h, treated with CPZ for 1 min, then washed
and inhibitors were added back for additional 2 h incubation at
37u. Cells were fixed and stained with TRITC-conjugated CTX
(CTX-555, red), and counterstained with TO-PRO3 (blue).
Images were collected using an oil objective (magnification X63).
Images were cropped but relative cell size was maintained.
Found at: doi:10.1371/journal.ppat.1000956.s008 (7.06 MB
DOC)
Figure S9 A-MLV Env- and VSV-G-induced cell-cell fusion is
unaffected by IMB or CPZ. U87.CD4.CCR5 cells were pre-
treated for 1 h with DMSO or 10 mM IMB, incubated with CHO-
K1 cells expressing A-MLV Env or VSV-G for 1 h, treated with
CPZ for 1 min, then washed and inhibitors were added back for
additional 2 h incubation at 37u. Cells were fixed and stained with
TRITC-conjugated CTX (CTX-555, red), and counterstained
with TO-PRO3 (blue). Images were collected using an oil
objective (magnification X63). Images were cropped but relative
cell size was maintained.
Found at: doi:10.1371/journal.ppat.1000956.s009 (9.94 MB TIF)
Figure S10 The actin monomer sequestering drugs LA and LB
and the dynamin inhibitor DYN block HIV-1 Env-dependent cell-
cell fusion, virus-dependent cell-cell fusion, virus-cell fusion and
infection. (A) Serum starved U87.CD4.CCR5 cells or U87.CD4.
CXCR4 cells were treated with DMSO alone, 1 mM TAK-779,
1 mM AMD3100, 1 mM LA, 5 mML B ,o r8 0mMD Y Nf o r1ha n d
these cells were used inan (A) Env-dependent cell-cellfusion assay or
a (B) virus-dependent cell-cell fusion assay and b-gal activity was
measured. Cell fusion was normalized using DMSO treated cells
mixed withHIVHXB2orHIVYU2(A)Env-expressingcellsor(B)virus
as 100%. (C & D) TZM-BL cells were incubated for 1 h with
DMSO, 1 mM TAK-779, 1 mMA M D 3 1 0 0 ,1mML A ,5mML B ,
80 mMD Y N ,t h e n1 5 0n go f( A )H I V HXB2 HIVADA or HIVYU2
virus was added for 90 min and BlaM activity was measured or (B)
150 ng HIVYU2 or HIVHXB2 virus was added for 3 h, washed,and
cells were incubated with inhibitors at 37uC overnight. Virus cell
fusion and infection were normalized using DMSO treated cells
infected with (C) HIVHXB2 or (D) HIVYU2 virus as 100%. Data are
representative of results from three similar experiments performed in
triplicate.
Found at: doi:10.1371/journal.ppat.1000956.s010 (1.65 MB TIF)
Figure S11 The dynamin inhibitor DYN blocks A-MLV-Env
and VSV-G-mediated infection to a greater extent than HIV-1
Env mediated infection. TZM-BL cells were incubated for 1 h
with DMSO, 1 mM TAK-779, 1 mM AMD3100, 40 mM DYN,
80 mM DYN, or 160 mM DYN, then 150 ng of HIVHXB2
HIVYU2, A-MLV-Env-HIV-1, or VSV-G-HIV-1 was added for
3 h, washed, and cells were incubated with inhibitors at 37uC
overnight. Virus cell fusion and infection were normalized using
DMSO treated cells infected with HIV-1 virus as 100%. Data are
representative of results from three similar experiments performed
in triplicate.
Found at: doi:10.1371/journal.ppat.1000956.s011 (1.29 MB TIF)
Table S1 Quantification of cell-cell hemifusion assay.
Found at: doi:10.1371/journal.ppat.1000956.s012 (0.03 MB
DOC)
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